Warning, Design Defect Claims Proceed In Widow’s Enbrel Wrongful Death Lawsuit

A Nebraska widow may proceed with claims that the arthritis treatment Enbrel carried an inadequate warning of a certain type of blood cancer that contributed to her husband’s death, the a federal trial court held Sept. 29 (Vallejo v. Amgen, Inc., D. Neb., 8:14-cv-00050-LSC-CRZ, 9/29/14).

Judge Laurie Smith Camp of the U.S. District Court for the District of Nebraska declined to dismiss the failure-to-warn claims. She also allowed Jan Vallejo’s design defect claims against manufacturers Amgen Inc., Wyeth Inc., and Pfizer Inc.

Steve Vallejo began using Enbrel in 2004 to treat rheumatoid arthritis. He developed complications from ...